| Company Name: |
Tcichem, Inc. |
| Tel: |
13918644899 |
| Email: |
81587635@qq.com |
|
| | 1-phenyl-2-(pyridin-2-yl)ethanamine Basic information |
| | 1-phenyl-2-(pyridin-2-yl)ethanamine Chemical Properties |
| Boiling point | 160 °C(Press: 2 Torr) | | density | 1.097±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 100 mg/mL (504.39 mM) | | form | Liquid | | pka | 8.29±0.10(Predicted) | | color | Colorless to light yellow |
| | 1-phenyl-2-(pyridin-2-yl)ethanamine Usage And Synthesis |
| Uses | (Rac)-Lanicemine ((Rac)-AZD6765) is the racemate of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects[1]. | | in vivo | Lanicemine produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects[1].
Lanicemine (3, 10 or 30 mg/kg; intraperitoneal) not only engages brain circuits involved in the generation of gamma- electroencephalography (EEG), but also influences these networks independent of the broader systems-level disruptions typical of ketamine[1]. | Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 3, 10 or 30mg/kg | | Administration: | Intraperitoneal | | Result: | Produced pronounced dose-dependent elevations in spontaneous gamma-band EEG, but only gamma changes for Ketamine were tightly coupled to increases in locomotor activity. |
| | IC 50 | NMDA Receptor | | References | [1] Sanacora G, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacywith minimal psychotomimetic adverse effects. Mol Psychiatry. 2014 Sep;19(9):978-85. DOI:10.1038/mp.2013.130 |
| | 1-phenyl-2-(pyridin-2-yl)ethanamine Preparation Products And Raw materials |
|